Search results for "DIFFERENTIATION FACTOR 11"

showing 2 items of 2 documents

GDF11 induces mild hepatic fibrosis independent of metabolic health

2020

BACKGROUND & AIMS: Growth Differentiation Factor 11 (GDF11) is an anti-aging factor, yet its role in liver diseases is not established. We evaluated the role of GDF11 in healthy conditions and in the transition from non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH). RESULTS: GDF11 mRNA levels positively correlated with NAFLD activity score and with CPT1, SREBP, PPAR? and Col1A1 mRNA levels, and associated to portal fibrosis, in morbidly obese patients with NAFLD/NASH. GDF11-treated mice showed mildly exacerbated hepatic collagen deposition, accompanied by weight loss and without changes in liver steatosis or inflammation. GDF11 triggered ALK5-dependent SMAD2/…

Liver CirrhosisMaleAgingSettore MED/09 - Medicina Interna*liverLiver Cirrhosis ExperimentalFetgeWeight lossFibrosisfibrosis; growth differentiation factor 11; liver; NAFLD; NASHNon-alcoholic Fatty Liver DiseaseGrowth differentiation factor 11Fatty liverNASH*fibrosisMiddle AgedObesity MorbidGrowth Differentiation FactorsLiverBone Morphogenetic ProteinsDisease ProgressionFemalemedicine.symptomResearch PaperSignal TransductionAdultmedicine.medical_specialtygrowth differentiation factor 11Inflammationliverdigestive systemCell LineEnvellimentInternal medicineNAFLDmedicineHepatic Stellate CellsAnimalsHumansddc:612*growth differentiation factor 11business.industry*NAFLDfibrosisnutritional and metabolic diseasesCell Biologyliver NAFLD NASH fibrosis growth differentiation factor 11*NASHmedicine.diseaseFibrosisdigestive system diseasesMice Inbred C57BLEndocrinologyPortal fibrosisCase-Control StudiesGDF11Hepatic stellate cellSteatohepatitisHepatic fibrosisbusiness
researchProduct

Systemic blockade of ACVR2B ligands protects myocardium from acute ischemia-reperfusion injury

2019

Activin A and myostatin, members of the transforming growth factor (TGF)-β superfamily of secreted factors, are potent negative regulators of muscle growth, but their contribution to myocardial ischemia-reperfusion (IR) injury is not known. The aim of this study was to investigate if activin 2B (ACVR2B) receptor ligands contribute to myocardial IR injury. Mice were treated with soluble ACVR2B decoy receptor (ACVR2B-Fc) and subjected to myocardial ischemia followed by reperfusion for 6 or 24 h. Systemic blockade of ACVR2B ligands by ACVR2B-Fc was protective against cardiac IR injury, as evidenced by reduced infarcted area, apoptosis, and autophagy and better preserved LV systolic function fo…

MaleActivin Receptors Type IIiskemialihaksetSmad2 ProteinMyostatinPharmacologyMice0302 clinical medicineDrug DiscoverykasvutekijätMyocytes CardiacCardioprotection0303 health sciences318 Medical biotechnologybiologysydänactivins1184 Genetics developmental biology physiologyII RECEPTORS3. Good health030220 oncology & carcinogenesisMolecular MedicineOriginal ArticleSignal TransductionCardiac function curvegrowth differentiation factorsProgrammed cell deathBLOCKINGischemia-reperfusion injuryIschemiaMyocardial Reperfusion InjuryMASSta311103 medical and health sciencesMYOSTATIN-KNOCKOUTCARDIOPROTECTIONGeneticsmedicineAnimalsMolecular Biologylihassolut030304 developmental biologyPharmacologySKELETAL-MUSCLE GROWTHbusiness.industryMyocardiumFOLLISTATINMyostatinmedicine.diseaseACVR2BMice Inbred C57BLACTIVIN-AGDF11GDF11biology.protein3111 BiomedicineproteiinitbusinessReperfusion injuryDIFFERENTIATION FACTOR 11ACVR2BTranscription Factors
researchProduct